Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis.
about
Bench-to-bedside review: Pulmonary–renal syndromes – an update for the intensivistEffectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosisMycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial.Management of ANCA-associated vasculitis: Current trends and future prospectsPopulation pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis.The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room.Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease.Mycophenolate mofetil in systemic vasculitis.Mycophenolate mofetil in patients with hepatitis C virus infection.Early termination of a trial of mycophenolate mofetil for treatment of interstitial cystitis/painful bladder syndrome: lessons learned.Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy durationUpdate on diffuse alveolar hemorrhage and pulmonary vasculitis.Pulmonary manifestations of anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis.Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cellsCurrent pharmacotherapy for the treatment of crescentic glomerulonephritis.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs.Renal transplantation in the ANCA-associated vasculitides.Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis.Pharmacotherapy of vasculitis.An approach to the diagnosis and management of systemic vasculitis.Wegener's granulomatosis of the orbit: a review of clinical features and updates in diagnosis and treatment.Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?Long-term outcome of mycophenolate mofetil treatment for patients with microscopic polyangiitis: an observational study in Chinese patients.Use of mycophenolate in ANCA-associated renal vasculitis: 13 years of experience at a university hospital.Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil.Hypogonadism in Wegener's granulomatosis.Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center.Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis.Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes.Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study.
P2860
Q27485164-EBC03C88-3ECC-48C9-BE21-B0AEB9227F3FQ33602730-CB865449-2B93-459B-AF8D-D0A24EC96EC6Q33684065-4872E337-B1CD-4E8E-A6FD-D41AB4B05394Q33947599-715971FB-5276-450C-868E-A6CFB23A258EQ34152549-FEE5C492-EF37-4B4F-B444-02A5EA6E044AQ34536203-E06495C1-5D50-42BF-AEBB-FE4267088D71Q35310520-938F4273-173B-4FE0-B7CD-CA7193E80EF0Q36085877-C8D8D659-E566-4B6F-89E8-CD16D9BB6A6CQ36085885-53AC0E5A-4B10-45EF-A619-C73543A72D8DQ36128533-4C796B68-C8CC-40D6-8DBC-252F3B0A7E21Q36193516-0F836FDA-20DB-4C72-9E2E-C8DCCDAF7C52Q36354929-A90A4814-2EDE-4F1D-A363-60DB12B92864Q36370934-63316C20-FB76-4590-A031-2CD5846E0DBDQ36420503-58CD12AC-4021-4478-B881-8014986A5B92Q36623061-687AA25B-8747-4467-9494-8C83498C0F43Q36724093-0311A924-EE02-4B09-9A9D-2D1851E9577FQ36802625-BCC3A72D-A4E4-4BB2-A6C4-C1D7052CA4A1Q36956903-AC39F0BE-82B2-458C-AF3D-F83D12B6CDF1Q37423423-4CE49A80-94D0-4B68-9B2B-554737075C00Q37483910-E54F28F7-4130-43B9-B5AA-18A26E9816D7Q37673239-4A3C21FC-5FBE-42BB-868F-067B45401586Q37940606-A75D02CB-8FA4-4E46-A558-433BB4D553E0Q38860793-564D4E25-5AFB-4C68-B417-6188286E02EEQ40678626-1D4DBF36-1948-4BA7-BC92-7412883A4430Q41387480-A3E08811-AEED-43E4-9AF3-AA3C022DD63FQ44600058-3709E3C3-C2BC-49DD-B150-D99948F788ECQ45334607-5BDE4ACB-08DC-4B7A-B995-E3EEE1E6309BQ46516731-3851416A-388E-487B-9ACA-91E0BE88C77FQ46673746-69BABDFD-C1EC-4501-9D2D-9BCC46D5956BQ46724327-C3C88CCC-BA5C-4AF6-86FF-306D33BAD9DDQ49691317-61D04B0F-E5C8-46CD-ABD3-70CAB5ED853FQ51768893-5CC147D5-A77E-46DD-B608-54726BE21B82
P2860
Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Mycophenolate mofetil for remi ...... t of Wegener's granulomatosis.
@en
Mycophenolate mofetil for remi ...... t of Wegener's granulomatosis.
@nl
type
label
Mycophenolate mofetil for remi ...... t of Wegener's granulomatosis.
@en
Mycophenolate mofetil for remi ...... t of Wegener's granulomatosis.
@nl
prefLabel
Mycophenolate mofetil for remi ...... t of Wegener's granulomatosis.
@en
Mycophenolate mofetil for remi ...... t of Wegener's granulomatosis.
@nl
P2093
P2860
P356
P1476
Mycophenolate mofetil for remi ...... t of Wegener's granulomatosis.
@en
P2093
Carol A Langford
Cheryl Talar-Williams
Michael C Sneller
P2860
P304
P356
10.1002/ART.20240
P577
2004-04-01T00:00:00Z